Patient Experiences with Clostridioides difficile Infection: Results of a Canada-Wide Survey

References

• Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. Can Med Assoc J. 2004;171(1):51–58. doi:10.1503/cmaj.1031189
   PubMed Web of Science ®Google Scholar
• Zoutman DE, Ford BD. A comparison of infection control program resources, activities, and antibiotic resistant organism rates in Canadian acute care hospitals in 1999 and 2005: pre- and post-severe acute respiratory syndrome. Can J Infect Control off J Community Hosp Infect Control Assoc = Rev Can Prev Des Infect. 2009;24(2):109–115.
   Google Scholar
• Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16 Suppl 4:S214–8. doi:10.1093/clinids/16.Supplement_4.S214
   Web of Science ®Google Scholar
• Rees WD, Steiner TS. Adaptive immune response to Clostridium difficile infection: a perspective for prevention and therapy. Eur J Immunol. 2018;48(3):398–406. doi:10.1002/eji.201747295
   Web of Science ®Google Scholar
• Furuya-Kanamori L, Marquess J, Yakob L, et al. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect Dis. 2015;15(1):1–11. doi:10.1186/s12879-015-1258-4
   Web of Science ®Google Scholar
• Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145(10):758. doi:10.7326/0003-4819-145-10-200611210-00008
   PubMed Web of Science ®Google Scholar
• Alfa MJ, Du T, Beda G. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol. 1998;36(7):2076–2080.
   PubMed Web of Science ®Google Scholar
• Hyland M, Ofner-Agostini M, Miller M, Paton S, Gourdeau M, Ishak M. N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project. Can J Infect Dis. 2001;12(2):81–88.
   Google Scholar
• Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48(5):568–576. doi:10.1086/596703
   Web of Science ®Google Scholar
• Cochrane BS, Hagins M, King JA, Picciano G, McCafferty MM, Nelson B. Back to the future: patient experience and the link to quality, safety, and financial performance. Healthc Manag Forum. 2015;28(6_suppl):S47–S58. doi:10.1016/j.ajodo.2015.07.024
   Google Scholar
• Madeo M, Shields L, Owen E. A pilot study to investigate patients reported knowledge, awareness, and beliefs on health care-associated infection. Am J Infect Control. 2008;36(1):63–69. doi:10.1016/j.ajic.2007.01.008
   PubMed Web of Science ®Google Scholar
• Madeo M, Boyack M. Using the lived experiences of patients with Clostridium difficile infection to improve care. Nurs Times. 2010;106(36):10–13.
   Google Scholar
• Becker HM, Grigat D, Ghosh S, et al. Living with inflammatory bowel disease: a Crohn's and Colitis Canada survey. Can J Gastroenterol Hepatol. 2015;29(2):77–84. doi:10.1155/2015/815820
   PubMed Web of Science ®Google Scholar
• Delate T, Albrecht G, Won K, Jackson A. Ambulatory-treated Clostridium difficile infection: a comparison of community-acquired vs. nosocomial infection. Epidemiol Infect. 2015;143(6):1225–1235. doi:10.1017/S0950268814001800
   Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615
   PubMed Web of Science ®Google Scholar
• Tieu JD, Williams RJ, Skrepnek GH, Gentry CA. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther. 2018;(June):1–9. doi:10.1111/jcpt.12771
   Web of Science ®Google Scholar
• Wilcox MH, Howe R. Diarrhoea caused by clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995;36(4):673–679. doi:10.1093/jac/36.4.673
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2017;66(7):e1–e48. doi:10.1093/cid/cix1085
   Web of Science ®Google Scholar
• Loo VG, Davis I, Embil J, et al. Association of medical microbiology and infectious disease Canada treatment practice guidelines for Clostridium difficile infection. Off J Assoc Med Microbiol Infect Dis Canada. 2018;3(2):71–92. doi:10.3138/jammi.2018.02.13
   Google Scholar
• Daniels LM, Kufel WD. Clinical review of Clostridium difficile infection: an update on treatment and prevention. Expert Opin Pharmacother. 2018;00(00):1–11. doi:10.1080/14656566.2018.1524872
   Web of Science ®Google Scholar
• Levy AR, Szabo SM, Lozano-Ortega G, et al. Incidence and costs of Clostridium difficile infections in Canada. Open Forum Infect Dis. 2015;2(3):ofv076. doi:10.1093/ofid/ofv076
   Web of Science ®Google Scholar
• Wilkinson K, Gravel D, Taylor G, et al. Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions. Am J Infect Control. 2011;39(3):177–182. doi:10.1016/j.ajic.2011.01.007
   Web of Science ®Google Scholar
• Nanwa N, Sander B, Krahn M, et al. A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions. PLoS ONE. 2017;12(3):e0172410. doi:10.1371/journal.pone.0172410
   Web of Science ®Google Scholar